A prospective, single-center, single-arm trial evaluated the feasibility and safety of the ETcath200 robotic PCI system in 20 patients with unstable angina and complex coronary anatomy (AHA/ACC type B2 or C lesions). The study had no comparator group and followed patients for 30 days. The primary aim was to assess procedural performance rather than a formally defined clinical outcome.
Regarding procedural results, technical success—defined as full robotic completion without unplanned manual input—was achieved in 16 of 20 cases (80%). Clinical success, defined as residual stenosis <30% with TIMI 3 flow and no in-hospital major adverse cardiovascular events (MACE), was achieved in all 20 patients (100%). The mean procedure duration was 61.0 ± 23.3 minutes, and the mean radiation dose was 0.07 ± 0.04 mSv.
Safety monitoring found one guidewire-induced dissection, which was managed successfully. There were no device failures, MACE, or serious adverse events reported at the 30-day follow-up. Key limitations include the single-center design, small sample size (n=20), lack of a comparator arm, and short follow-up duration. The study was not designed to establish efficacy or compare outcomes to manual PCI.
For clinical practice, these data represent an early technical assessment in a highly selected population. The results support the feasibility of further, more rigorous investigation in multicenter trials. Clinicians should interpret these findings cautiously and await comparative effectiveness and long-term safety data before drawing conclusions about the system's role in routine care.
View Original Abstract ↓
BACKGROUND: International robotic-assisted PCI platforms such as CorPath 200 and CorPath GRX have demonstrated procedural safety and efficacy but are limited by the absence of real-time tactile feedback and cumbersome device exchange. The ETcath200, the first domestically developed robotic PCI system in China, introduces guidewire force-sensing to provide real-time visual resistance feedback that partially compensates for the lack of direct tactile sensation, along with streamlined device exchange and an intuitive joystick-roller interface.
AIMS: This study aimed to evaluate the feasibility, safety, and procedural performance of the ETcath200 system in patients with complex coronary lesions.
METHODS: In this prospective, single-center, single-arm trial, 20 patients with AHA/ACC type B2 or C complex coronary lesions underwent PCI using the ETcath200 system. Technical success was defined as full robotic completion without any unplanned manual input (including partial manual assistance or manual conversion); clinical success as residual stenosis < 30% with TIMI 3 flow and no in-hospital major adverse cardiac events (MACE). Patients were followed for 30 days.
RESULTS: All 20 patients (mean age 63.2 ± 12.0 years; 80% male) had unstable angina and complex coronary anatomy (79.2% type C lesions; 50% bifurcation, 65% diffuse). Most procedures were performed via radial access (80%), and the majority utilized drug-eluting stents (65%). Technical success was achieved in 16 cases (80%), while four cases (20%) required manual conversion due to severe tortuosity or calcification (n = 3) or guidewire-induced dissection (n = 1; managed successfully). All patients achieved clinical success; no device failures, MACE, or serious adverse events occurred at 30 days. Mean procedure duration was 61.0 ± 23.3 min; radiation dose was 0.07 ± 0.04 mSv.
CONCLUSIONS: The ETcath200 robotic PCI system demonstrated feasibility, safety, and reliable performance in complex coronary lesions, achieving high clinical success and excellent short-term outcomes. Manual conversion was required only in anatomically challenging cases. These data support further multicenter evaluation of ETcath200 in complex coronary interventions.